Qiming Venture Partners and Portfolio Companies Win Multiple ChinaVenture Awards, Including Top 5 China VC Firm of 2024
The "ChinaVenture Rankings" have been published for 19 consecutive years, recognized within the industry for their professionalism, authority, and rigor. They are widely regarded as a bellwether for China's equity investment sector and serve as a key reference for capital commitments from many large institutional LPs.
ChinaVenture today released its flagship annual ranking of Chinese venture capital and private equity institutions — the "ChinaVenture Rankings." Now in its 19th consecutive year, the rankings are recognized throughout the industry for their professionalism, authority, and rigor, serving as a bellwether for China's equity investment sector and a key reference point for major institutional LPs when making allocation decisions. Qiming Venture Partners and its portfolio companies received multiple awards.
This year's rankings cover categories including Best VC Firms, Best PE Firms, Best Early-Stage VC Firms, Best Industry-Focused Investors, and Best Industry Investment Cases of the Year. In the institutional categories, Qiming Venture Partners won numerous honors.
Qiming Venture Partners
Honored with
Top 5 Best VC Firms in China
Top 3 Best Foreign VC Firms in China
Top 10 Best VC Firms by Returns in China
Best VC Fundraising Team in China
Top 30 Best Investors in AI and Big Data in China
Top 30 Best Investors in Digitalization and IT in China
Top 30 Best Investors in Biopharma — Healthcare and Health Services in China
Top 20 Best Investors in Medical Devices — Healthcare and Health Services in China
Top 10 Best Investors in Medical Services — Healthcare and Health Services in China
In the company categories, Qiming portfolio companies StepFun, Infinigence AI, Zhipu AI, DeepWay, Chaitin, Lattice Power, and Pelliot were named Best Industry Investment Cases.
StepFun, Infinigence AI, Zhipu AI
Named to
Top 10 Best Investment Cases in AI and Big Data in China
DeepWay
Named to
Top 10 Best Investment Cases in Advanced Manufacturing — Advanced Manufacturing and High-Tech in China
Chaitin
Named to
Top 10 Best Investment Cases in Digitalization and IT in China
Lattice Power
Named to
Top 10 Best Investment Cases in Carbon Neutrality in China
Pelliot
Named to
Top 10 Best Investment Cases in New Consumer in China
· 2024 ChinaVenture Rankings
Drawing on CVSource data and surveys of over 1,000 active PE investment institutions, the ChinaVenture research team verified data against selection criteria to identify outstanding firms.
The ChinaVenture research team found that the secondary market is undergoing comprehensive restructuring, which in turn is reshaping the exit ecosystem for PE investors. Firms need to build more diversified exit strategies.
As the primary market enters a peak of "differentiation," the industry landscape will be reconfigured, with deep transformations in value, philosophy, and strategy. Over nineteen years, the ChinaVenture Rankings have borne witness to the wisdom and courage of China's private equity investors as they navigate destruction and creation.
Source | ChinaVenture
Past Coverage
Qiming Headlines | Qiming Venture Partners and Portfolio Companies Win Multiple Honors at 2023 ChinaVenture Rankings Including Best VC Firm in China Qiming Honors | Qiming Venture Partners Ranks 5th in Zero2IPO 2024 Best VC Firms in China, Among Five Awards Qiming Honors | Qiming Venture Partners Named Most LP-Focused VC Firm in China at ChinaVenture 2024
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Consumer (T&C) and Healthcare.
To date, Qiming has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the NYSE, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), GenScript ProBio (688520.SH), Yuanxin Technology, ClinChoice, Belief BioMed, Biren Technology, among others.